Innovative R&D

Innovation is the cornerstone of GenePlus's precision medicine mission. Spanning oncology, infectious disease, and beyond, we tackle critical clinical questions through global collaboration across hospitals, academia, and industry, and we translate genomic and AI breakthroughs into real-world impact that advances human health.

CMotor AI Engine

CMotor is an AI-agent platform developed by GenePlus and the underlying engine that powers AI4BT. Grounded in real clinical questions, it formulates mechanistic hypotheses and validates them with authentic omics data, producing both biomarkers and candidate targets as complementary outputs. Its first deployed agents are Mindclaw, Geneclaw, 6Dmarker, and B2T, which together cover the full workflow from study design and data analysis to model generation and target inference.

AI Foundation Models

GenoVision Multimodal Foundation Model

The first NGS-omics-powered pathology foundation model for precision subtyping.

GenoVision integrates diverse data modalities, including NGS reports, pathology images, medical imaging, and clinical information, into a single interpretable output that supports both clinical decisions and research discovery.

GenoVision multimodal fusion report with NGS, pathology, imaging, and clinical inputs

Product Highlights

Best-in-Class Performance

Combines leading pathology and imaging foundation models, trained on hundreds of thousands of clinical samples for superior accuracy and efficiency.

Seamless & Efficient

Works with all clinical data types, including pathology, NGS, imaging, and text, with no additional data collection or format conversion required.

Highly Interpretable

Visualizes molecular weights and attention heatmaps to make complex results intuitive and actionable for downstream interpretation.

Applications

Benign-Malignant Tumor Classification

Tumor Recurrence & Metastasis Prediction

ADC Biomarker Discovery

Tumor Immune Microenvironment Assessment

Intelligent Data Analysis & Management

Geneclaw runs bioinformatics analysis through natural language on GenePlus's AI multi-omics platform, accelerating data mining. With V-USE, an intelligent biomarker platform powered by the 6Dmarker model, it delivers end-to-end AI-driven data services.

Geneclaw Intelligent Bioinformatics Analysis Platform

Geneclaw is GenePlus's fully managed cloud-based intelligent analysis platform. Through a single A2A interface, users can access hundreds of omics tools, with 24/7 cloud operation and automatically delivered results. It also supports custom Skills and team sharing, helping every researcher unlock deeper value in their data.

Fully Managed

24/7 cloud delivery, zero token cost, zero on-call, and automatically delivered results.

High Success Rate

Five sub-agent types with three independent review checkpoints, achieving a success rate above 94%.

High Quality

Auto-checked results with README files and readable, reproducible deliverables.

Effortless

One A2A interface unlocks full omics capabilities.

Extensible

Custom Skills and team sharing keep expanding your analysis power.

Major Disease R&D Directions

Grounded in clinical problems, GenePlus focuses on core areas such as oncology and infectious disease, and extends into multiple key directions including organ transplantation and cardiovascular and cerebrovascular diseases, continuously pursuing technological innovation and breakthroughs in clinical value.

Flagship Achievements

As of September 2026, GenePlus has published over 500 SCI-indexed papers in leading international journals including Nature, Nature Medicine, Cancer Cell, and Cancer Discovery, with a combined impact factor exceeding 4,400. The company has also been granted more than 260 patents and software copyrights. In addition, GenePlus has actively contributed to over 50 national-level major research initiatives, including more than 10 national research programs, and has partnered with industry experts to develop over 20 industry standards and consensus documents, strengthening the foundation for technological innovation and clinical application.

Selected Publications